INTRODUCTION
============

Cancer is a major public health problem in most developed countries; however, there have been notable improvements in the survival rate of patients over the past three decades owing to early detection and progress in medical treatment ([@B12]; [@B53]). A substantial number of patients with cancer receive chemotherapy or chemoradiotherapy and benefit from treatment with anticancer drugs ([@B12]). However, because of their toxic effects on normal cells/tissues, anticancer drugs cause many side effects with a variety of symptoms, such as nausea, vomiting, anorexia, diarrhea, oral mucositis, and numbness. These side effects often compromise patients' quality of life (QOL) and sometimes make it difficult to continue chemotherapy or chemoradiotherapy ([@B2]). Although many valuable strategies have been developed to treat or prevent these side effects, they are still insufficient ([@B15]; [@B39]; [@B20]; [@B27]). Therefore, an alternative or novel approach to treat or prevent these side effects is required.

Japanese traditional herbal medicines, called Kampo, were imported from China 1,500 years ago and developed independently ([@B42]). Kampo medicines are currently prescribed by more than 80% of medical doctors in Japan and are covered by National Health Insurance. In recent years, several Kampo medicines have been investigated using animal models and clinical trials to assess their effects on chemotherapy-induced side effects. In this review, we describe the current status of several Kampo medicines in the treatment or prevention of chemotherapy-induced side effects as well as their underlying mechanisms.

RIKKUNSHITO FOR THE TREATMENT OF CISPLATIN-INDUCED ANOREXIA
===========================================================

CISPLATIN-INDUCED ANOREXIA
--------------------------

It is important to prevent and treat chemotherapy-induced side-effects such as anorexia, nausea, and vomiting to maintain patients' QOL and to continue chemotherapy safely ([@B21]). Nausea and vomiting are caused by activation of vagal afferent neurons through the release of 5-HT and substance P from the enterochromaffin cells in the gut via 5-HT3 and neurokinin (NK)-1 receptors, respectively. Antagonists of 5-HT3 and NK-1 receptors have been developed and are widely used for the treatment of chemotherapy-induced nausea and vomiting ([@B49]; [@B7]). On the other hand, anorexia has been reported to be associated with other 5-HT receptors; 5-HT2R or 5-HT3R antagonists are associated with a decrease in food intake, leading to anorexia, as concluded from animal experiments ([@B13]; [@B18]). 5-HT2CR is expressed mainly in the stomach ([@B62]), whereas 5-HT2BR expression is restricted to the central nervous system ([@B16]).

International guidelines for antiemetic use have recommended antagonists for 5-HT3 and NK-1 receptors as well as corticosteroids for patients undergoing treatment with anticancer drugs including cisplatin ([@B49]; [@B7]). However, the effect of this treatment is still insufficient, because the complete response rate and complete control rate have been reported to be 40--75%, and anorexia as an adverse event was reported in approximately 15% of patients ([@B22]; [@B48]; [@B51]). In addition, food intake decreased to 25% of baseline by 7 days after administration of chemotherapy including cisplatin ([@B24]). These results suggest that gastrointestinal symptoms such as nausea, vomiting, and anorexia following chemotherapy persist for several days in many patients.

Ghrelin is a GH-releasing peptide isolated from the stomach as an endogenous ligand for GH secretagogue receptor 1a (GHS-R1a; [@B26]), a G-protein-coupled orphan receptor ([@B31]). Ghrelin has 28 amino acids, with 3Ser acylated with an n-octanoyl residue, and this octanoylation is essential for the activation of ghrelin. Ghrelin is predominantly produced by the endocrine X/A-like cells of the stomach ([@B10]) and plays various physiological roles as a circulating hormone, such as inducing GH release and food intake. More than 90% of circulating ghrelin is in an inactive form called desacylghrelin; however, recent studies have demonstrated that this desacylghrelin is also physiologically active ([@B6]; [@B8]; [@B59]). Administration of ghrelin into the brain ventricles or veins of rodents induced food intake and weight gain ([@B43]). The hypothalamus has an arcuate nucleus that manages food intake, and certain food intake-stimulating neurons produce neuropeptide Y (NPY) and agouti-related protein (AgRP). The ghrelin receptor is expressed in the same neurons and is thus considered to stimulate food intake by activating the NPY/AgRP neurons ([@B43]). Ghrelin secreted from the stomach binds to the ghrelin receptor, which is produced in vagal afferent neurons and transported to the terminal of the afferent fiber, and inhibits electrical activity of the vagal afferent fiber. This signal is transmitted to the solitary nucleus in the medulla oblongata and then to the NPY and growth hormone releasing hormone (GHRH) neurons in the hypothalamus, leading to food intake and secretion of GH ([@B11]). Recent studies have demonstrated that the blood level of ghrelin decreases after chemotherapy including cisplatin in animals as well as in humans ([@B55]; [@B46]; [@B23]). Therefore, ghrelin may be involved in cisplatin-induced anorexia.

EFFECT OF RIKKUNSHITO ON CISPLATIN-INDUCED ANOREXIA
---------------------------------------------------

Rikkunshito is composed of 8 herbal medicines and is widely used in Japan to treat various gastrointestinal disorders ([@B56]; [@B63]). Through animal experiments, we demonstrated the following: (1) cisplatin decreases serum ghrelin levels; (2) antagonists for the 5-HT2B or 5-HT2C receptors recover the decrease in serum ghrelin levels and food intake caused by cisplatin, respectively; (3) rikkunshito recovers the decrease in serum ghrelin levels and food intake caused by cisplatin; and (4) the flavonoids present in rikkunshito have an antagonistic effect on the 5-HT2B and 5-HT2C receptors ([@B55]). [@B64],[@B65]) demonstrated that cisplatin decreases the expression of GHS-R1a and secretion of ghrelin in the hypothalamus via the 5-HT2C receptor, and rikkunshito ameliorates this effect. It has also been reported that rikkunshito antagonizes the 5-HT3 receptor ([@B58]).

Several clinical trials have been conducted to investigate the effect of rikkunshito on chemotherapy-induced anorexia. [@B46] performed a cross-over clinical trial using rikkunshito involving 10 patients with unresectable or recurrent gastric cancer treated with S-1 and cisplatin. They reported that rikkunshito attenuated the decrease in plasma acyl ghrelin levels, increased food intake during chemotherapy, and reduced the degree of anorexia caused by chemotherapy. [@B52] evaluated the effect of rikkunshito in 19 patients with advanced esophageal cancer treated with docetaxel, 5-FU, and cisplatin. They reported that rikkunshito ameliorated chemotherapy-induced nausea and vomiting and improved the QOL score, particularly for mood and daily activity.

HANGESHASHINTO FOR THE TREATMENT OF IRINOTECAN HYDROCHLORIDE (CPT-11)-INDUCED DIARRHEA
======================================================================================

CPT-11-INDUCED DIARRHEA
-----------------------

CPT-11 exerts an inhibitory effect on nucleic acid synthesis by inhibition of topoisomerase I and is widely used for the treatment of a variety of cancers ([@B50]). One of the dose-limiting toxicities is late onset diarrhea (beginning more than 24 h after infusion) that leads to dehydration and electrolyte imbalance, making it a life-threatening condition ([@B1]). The underlying mechanism for CPT-11-induced late onset diarrhea involves direct damage to the intestinal mucosa induced by SN-38, a metabolite of CPT-11 ([@B19]). CPT-11 is converted to SN-38, an active form of CPT-11 in the liver, and subsequently conjugates to inactive, non-toxic SN-38 glucuronide. Thereafter, SN-38 glucuronide is deglucuronidated to SN-38 by bacterial β-glucuronidase and induces mucosal damage and toxicity ([@B5]).

EFFECT OF HANGESHASHINTO ON CPT-11-INDUCED DIARRHEA
---------------------------------------------------

Hangeshashinto is composed of seven herbs and is often used in Japan to treat diarrhea and acute gastroenteritis ([@B28]). Hangeshashinto is known to slow the enterohepatic circulation of SN-38. Baicalin in hangeshashinto has been shown to inhibit the activity of β-glucuronidase as well as the synthesis of prostaglandin E2 ([@B44]; [@B28]). In an animal experiment, hangeshashinto, and baicalin exhibited protective effects against intestinal toxicity caused by CPT-11 ([@B54]). A randomized controlled trial was performed involving 41 patients with non-small cell lung cancer treated with cisplatin and CPT-11, and the grade of diarrhea significantly improved after treatment with hangeshashinto ([@B41]). In addition, hangeshashinto significantly reduced the frequency of severe diarrhea (grade 3 or 4). Furthermore, the frequency of diarrhea was less than that reported previously ([@B32]). Only 1 out of 15 patients who received 125 mg/m^2^ of CPT-11 suffered from grade 3 diarrhea.

HANGESHASHINTO FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED ORAL MUCOSITIS
=======================================================================

CHEMOTHERAPY-INDUCED ORAL MUCOSITIS
-----------------------------------

Oral mucositis is a common complication of chemotherapy, affecting 18--40% of patients after the first chemotherapy cycle ([@B37]). The morbidity of oral mucositis is primarily due to the pain associated with oral mucosal inflammation and ulceration, which affects food intake, oral hygiene, and QOL ([@B9]).

EFFECT OF HANGESHASHINTO ON CHEMOTHERAPY-INDUCED ORAL MUCOSITIS
---------------------------------------------------------------

Hangeshashinto contains several prostaglandin E2-regulating ingredients ([@B29]; [@B35]). In a retrospective study with a small number of patients (*N* = 14), topical application of hangeshashinto improved oral mucositis ([@B33]). [@B4] conducted a double-blind, placebo-controlled, randomized phase II study of hangeshashinto for oral mucositis induced by gastric cancer chemotherapy. Although hangeshashinto did not reduce the incidence of ≥2 oral mucositis, it tended to reduce the risk of oral mucositis in the patients who developed grade 1 oral mucositis. [@B66] investigated the effect of hangeshashinto for chemoradiation-induced mucositis in head and neck cancer patients, and hangeshashito was associated with a significantly improved rate of completion of chemoradiation with cisplatin. In addition, serum albumin level was significantly maintained better in the hangeshashinto group than in the control group. [@B38] are currently conducting a double-blind, placebo-controlled, randomized phase II study of hangeshashinto for oral mucositis induced by fluorinated pyrimidine-based colorectal cancer chemotherapy.

GOSHAJINKIGAN FOR THE TREATMENT OF OXALIPLATIN-INDUCED NEUROTOXICITY
====================================================================

OXALIPLATIN-INDUCED NEUROTOXICITY
---------------------------------

Oxaliplatin, a platinum compound, is widely used for the treatment of various cancers, mainly colorectal cancer. However, oxaliplatin-induced neurotoxicity is the most common dose-limiting side effect ([@B3]; [@B17]). Although the underlying mechanism of oxaliplatin-induced neurotoxicity is not fully understood, it has been suggested that oxaliplatin accumulates in the dorsal root ganglia and produces axonal hyperexcitability and repetitive discharges due to changes in voltage-dependent sodium channels ([@B47]; [@B14]).

EFFECT OF GOSHAJINKIGAN ON OXALIPLATIN-INDUCED NEUROTOXICITY
------------------------------------------------------------

Goshajinkigan is composed of 10 herbal medicines and is widely used in Japan for the treatment of rhigosis, numbness or pain in the extremities, low back pain, and diabetic neuropathy ([@B57]; [@B60]). Animal experiments have demonstrated that goshajinkigan prevents oxaliplatin-induced acute peripheral neuropathy without affecting its anti-tumor efficacy ([@B61]) by suppressing functional alterations of the transient receptor potential (TRP) channels, particularly TRPA1 and TRPM8 ([@B30]; [@B40]). Retrospective studies and randomized controlled trials with a small number of patients have demonstrated that goshajinkigan significantly reduces the incidence of neurotoxicity, prolongs the duration of oxaliplatin treatment, and delays the time to the onset of neurotoxicity ([@B36]; [@B45]; [@B25]). A placebo-controlled, double-blind randomized phase II study was conducted in patients with advanced or recurrent colorectal cancer treated with standard FOLFOX regimens; goshajinkigan appeared to have an acceptable safety margin and a promising effect in delaying the onset of grade ≥2 neurotoxicity without impairing FOLFOX efficacy ([@B34]). [@B67] evaluated the efficacy of goshajinkigan for oxaliplatin-induced neuropathy in patients with colorectal cancer and demonstrated that goshajinkigan prevented exacerbation of neuropathy.

CONCLUSION
==========

Growing evidence suggests that Kampo medicines appear to have beneficial effects for the treatment or prevention of several chemotherapy-induced side effects. Because each Kampo medicine is not composed of a single substance, further basic studies should clarify which of the substances are responsible for the beneficial effects as well as the underlying mechanism of action. Although it is sometimes difficult to set appropriate and subjective endpoints for Kampo medicines, placebo-controlled, double-blind, randomized clinical trials similar to those for Western medicine will provide decisive evidence.
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